Table 2.
Study characteristics and included data sets for CT and MRI of the included articles
| Study ID | Country | Study type | Patients (M/F) | Age (yr), mean (range) | Tumor location | Imaging modality | Unit |
|---|---|---|---|---|---|---|---|
| Adams et al28 1998 | Germany | P | 60 (16/44) | 58.3 (38–76) | Tongue, FOM, Palate, MAN, MAX | MRI, CT | node |
| Akoglu et al29 2005 | Turkey | P | 23 (19/4) | 58.3 (40–78) | Head and neck | MRI, CT | node |
| Anzai et al30 1994 | USA | P | 12 (7/5) | 39–78 | EAC, MAN, BCC, RMT, Lip, Oral cavity, Larynx | MRI | node |
| Ao et al31 1998 | Japan | R | 42 (9/33) | 60 (39–78) | Larynx | MRI, CT | node |
| Bondt et al32 2009 | The Netherlands | P | 16 (9/7) | 40–77 | Tongue, NP, RMT, SMG, Cheek, RMT, SP, Nose | MRI, CT | neck level |
| Braams et al33 1996 | The Netherlands | P | 11 (7/4) | 62.3 (46–73) | FOM, RMT, Cheek, Gingiva | MRI, CT | node |
| Braams et al34 1995 | The Netherlands | P | 12 (8/4) | 65.3 (48–85) | Tongue, Lip, Gingiva, RMT, FOM | MRI | node |
| Bruschini et al35 2003 | Italy | P | 22 (19/3) | 62.3 (46–79) | Larynx, OP, Oral cavity, Skin | CT | node |
| Curtin et al36 1997 | Canada | R | 213 (150/63) | 59.6 (18–84) | Oral cavity, OP, HP, Larynx | MRI, CT | neck level |
| Dammann et al37 2005 | Germany | P | 64 (43/21) | 56 (26–83) | Oral cavity, OP | MRI, CT | neck level |
| Ding et al38 2005 | People’s Republic of China | P | 92 (58/34) | 53 (24–81) | Tongue | MRI | neck level |
| Dirix et al39 2010 | Sweden | P | 22 (13/9) | 60 (41–83) | Oral cavity, Larynx, HP | MRI | node |
| Eida et al40 2003 | Japan | P | 111 (74/37) | FOM, Tongue, Palate, Gingiva, Cheek | CT | node | |
| Fan et al41 2006 | People’s Republic of China | R | 42 (37/5) | 53.6 (45–70) | OP, HP, Cervical esophageal | CT | patient |
| Fukunari et al42 2010 | Japan | R | 20 | 58 (23–81) | Tongue, Gingiva, Buccal, MAN, FOM | MRI | node |
| Gross et al43 2001 | USA | R | 26 (8/18) | 40 (10–80) | Thyroid | MRI | node |
| Gu et al44 2000 | People’s Republic of China | P | 62 | 58 (44–77) | Head and neck | MRI | node |
| Guenzel et al45 2013 | Germany | P | 120 (95/25) | 41–85 | OP, Larynx | MRI | node |
| Guo et al46 2006 | People’s Republic of China | R | 48 (28/20) | 56 (21–66) | Tongue, Buccal, Gingiva, FOM, Palate | MRI | node |
| Hannah et al47 2002 | Australia | P | 48 (34/14) | 61 (26–92) | Oral cavity, OP, SGL, HP | CT | neck level |
| Hao et al48 2000 | People’s Republic of China | P | 60 | Tongue, Gingiva, FOM, Palate, RMT, Buccal, Larynx, HP | MRI | node | |
| Hafidh et al49 2006 | Ireland | R | 48 (42/6) | 56 (32–80) | Oral cavity, OP, HP, Paranasal sinuses, Ear(skin) | MRI, CT | node |
| Hlawitschka et al50 2002 | Germany | P | 38 (28/10) | 59 (41–89) | Tongue, Buccal, Palate, MAX | MRI, CT | node |
| Hoffman et al51 2000 | USA | P | 9 (6/3) | 43–76 | Oral cavity, OP, Lip | MRI | node, neck level |
| Jeong et al52 2007 | Greece | R | 47 (41/6) | 56.3 | Oral cavity, Larynx, OP, HP, PG | CT | neck level |
| Kau et al53 1999 | Germany | P | 111 (95/16) | 29–78 | Larynx, OP, LP, Lip, Ear | MRI, CT | node, neck level |
| Kawai et al54 2005 | Japan | P | 29 (23/6) | 60 (28–81) | Tongue, OP, NP, Larynx, Buccal, Palate, PG, Gingiva | MRI | neck level |
| Ke et al55 2006 | People’s Republic of China | R | 20 (15/5) | 54.5 (31–69) | Tongue, Larynx, Thyroid gland | CT | node |
| Krabbe et al56 2008 | The Netherlands | P | 38 (21/17) | 59 (53–680) | Tongue, Gingiva, FOM, Tonsillar fossa | MRI, CT | node |
| Laubenbacher et al57 1994 | Germany | P | 22 (20/2) | 54.4 (38–70) | OP, HP | MRI | node, neck level |
| Lee et al58 2013 | People’s Republic of China | P | 22 (21/1) | 49.8 (26–66) | Tongue, Buccal, OP, FOM, HP, Palate, RMT, epiglottis, Pyriform sinus | MRI | patient |
| Lu et al59 2007 | People’s Republic of China | P | 13 (11/2) | 58 (47–71) | Oral cavity, HP, OP, Larynx | CT | node |
| Lwin et al60 2012 | UK | R | 102 (68/34) | 59 (23–89) | Tongue, FOM, Palate, Buccal, RMT, Tonsil, Gingiva | MRI | patient |
| Mcguirt et al61 1995 | UK | P | 49 | Oral cavity, OP, HP | CT | node | |
| Nakamoto et al62 2009 | Japan | R | 65 (50/15) | 62 (27–81) | Larynx, HP, MAX, Tongue, OP, PG, Gingiva, FOM, NP, Ethmoid, EAM, Thyoid | MRI | patient |
| Nishimura et al63 2006 | Japan | P | 16 (13/3) | 65.8 (37–76) | Cervical Esophageal | MRI | node |
| Olmos et al64 1999 | The Netherlands | P | 12 (6/6) | 61.8 (44–73) | OP, Larynx, HP, Tongue, MAX | MRI | neck level |
| Ou et al65 2007 | People’s Republic of China | R | 24 (19/5) | 50 (23–80) | Tongue, OP, Palate, Cheek, Maxillary sinus, Branchial cleft | MRI | node |
| Paulus et al66 1998 | Belgium | R | 25 (21/4) | 48–74 | SGL, Tongue, Glottis, Palate, RMT, FOM, HP, Vocal cord, Vestibule, Pyriform sinus | CT | node |
| Perrone et al67 2011 | Italy | R | 17 (10/7) | 63 (15–85) | Head and neck | MRI | patient |
| Peters et al68 2013 | The Netherlands | R | 149 (120/29) | 62 (40–78) | SGL, Glottis, NP, Cervical Esophageal | MRI, CT | patient |
| Pohar et al69 2006 | USA | R | 25 (17/8) | 63.4 | Oral cavity, OP, HP, Larynx, Nasal cavity | CT | node, neck level |
| Ren et al70 2000 | People’s Republic of China | P | 20 (18/2) | 45–68 | SGL | CT | node |
| Schwartz et al71 2004 | USA | P | 20 (20/0) | 61 (42–78) | Oral cavity, OP | CT | node |
| Semedo et al72 2006 | Portugal | P | 20 (20/0) | 57.3 (36–78) | HP, Larynx, OP | MRI | node |
| Seitz et al73 2009 | Germany | R | 66 (39/27) | 63 (25–89) | Oral cavity, OP | MRI | node, patient |
| Stokkel et al74 2000 | The Netherlands | P | 54 (31/23) | 60 (34–81) | Tongue, FOM, Gingiva, RMT, OP | CT | node |
| Stuckensen et al75 2000 | Germany | P | 106 (89/17) | 59.6 (33–87) | FOM, Tongue, RMT, MAN, MAX, Buccal | MRI, CT | neck level |
| Sumi et al76 2007 | Japan | R | 38 (32/6) | 65 | HP, Gingiva, OP, Tongue, Larynx, FOM | MRI, CT | node |
| Sumi et al77 2006 | Japan | P | 26 | OP, Gingiva, Larynx, Tongue | MRI | node | |
| Sumi et al78 2003 | Japan | P | 32 | 24–80 | OP, Gingiva, FOM, Tongue, Buccal, EAC | MRI | node |
| Sun et al79 2013 | People’s Republic of China | R | 114 (60/54) | 51.2 (34–70) | Thyroid gland, Larynx, NP, HP, Tongue, PG, Cervical Esophageal, Maxillary sinus, Ear | CT | node |
| Sun et al79 2013 | People’s Republic of China | R | 86 (45/41) | 52.7 (35–75) | Thyroid gland, Larynx, NP, HP, Tongue, PG, Cervical Esophageal, Maxillary sinus, Ear | MRI | node |
| Tai et al80 2002 | People’s Republic of China | P | 40 (24/16) | 25–65 | NP | MRI | patient |
| Takashima et al81 1997 | Japan | R | 50 (13/37) | 57 (24–81) | Thyroid | MRI | node |
| Tuli et al82 2008 | India | P | 20 (12/8) | 54.75 (30–85) | Tongue | MRI, CT | patient |
| Van den Brekel et al83 1991 | The Netherlands | P | 100 | 63±12.8 | Tongue, FOM, SP, Lip, Tonsil, Pharyngeal wall, Ear, Tonsil, PS, SGL, Gingiva | MRI | patient |
| Vandecaveye et al84 2008 | Belgium | P | 36 | 41–81 | Nasal cavity, SGL, FOM, OP, Glottis, Tongue, HP | MRI | node, neck level, patient |
| Wang et al85 1999 | Japan | P | 14 (10/4) | 46 (26–71) | Thyroid | MRI | node |
| WIDE et al86 1999 | UK | R | 58 | 58.1 (32–82) | Tongue, FOM, Buccal, RMT, OP, Gingiva | MRI | neck level |
| Wilson et al87 1994 | UK | P | 12 | FOM, Tongue, Tonsillar, Skin, Pinna, PG, Thyroid | MRI | neck level | |
| Wu et al88 2010 | People’s Republic of China | R | 24 (23/1) | 53.6 (45–85) | Larynx, HP | CT | node |
| Yoon et al89 2008 | Korea | R | 67 (58/9) | 60 (24–85) | Larynx, Pharynx, Tonsil, Tongue, Oral cavity, Skin, MAX | MRI, CT | neck level |
| Yuan et al90 2000 | People’s Republic of China | R | 19 (12/7) | 42–66 | Larynx | MRI | neck level |
Abbreviations: M, male; F, female; R, Retrospective; P, Prospective; EAC, external auditory canal; BCC, branchial cleft cyst; PS, piriform sinus; SGL, supra-glottic larynx; TGL, trans-glottic larynx; CT, computed tomography; MRI, magnetic resonance imaging; FOM, floor of mouth; MAN, mandibule; MAX, maxilla; RMT, retro-molar trigonum; NP, nasopharynx; SMG, submandibular gland; OP, oropharynx; HP, hypopharynx; LP, laryngopharynx; PG, parotid gland; SP, supropharynx; yr, years.